ABSTRACT
@# Objective: To compare the safety and efficacy of bevacizumab plus cisplatin and cisplatin alone in the treatment of malignant pleural effusion of lung cancer patients. Methods: From November 2014 to November 2017, 27 patients diagnosed with lung cancer complicated with malignant pleural effusion at the department of Oncology, the Central Hospital of Huludao, were enrolled in this study. Fourteen patients received bevacizumab plus cisplatin and thirteen patients received cisplatin alone. The clinical efficacy and adverse reactions were compared between the two groups. Results: There was no significant difference in the general condition between the two groups before treatment(P>0.05). The bevacizumab group had better short-term efficacy than the cisplatin group and the difference was statistically significant(92.9% vs 61.5%, P<0.05). The main adverse reactions during the treatment were bone marrow suppression and gastrointestinal discomfort, etc. The incidence of adverse reactions was similar between the two groups, with no statistically significant difference(P>0.05). Conclusion: Compared with cisplatin alone, bevacizumab combined with cisplatin has better shortterm efficacy in the treatment of lung cancer patients with malignant pleural effusion. The adverse reactions were quite similar.
ABSTRACT
To study the expression of DNAJB11 protein in epithelial ovarian cancer tissues and its clinical significance.Immunohistochemistry was used to examine DNAJB11 expressions in 105 tissue specimens of ovarian epithelial carcinoma, 23 normal ovarian tissues, 17 tissues of benign tumor, and 13 tissues of of borderline tumor. The correlations between protein expression and clinicopathological factors were analyzed by Chi square test.The correlations between protein expression and survival were analyzed by Kaplan-Meier and Cox regression.Positive expression of DNAJB11 protein was observed in 0.0% in normal ovary and benign tumor, 7.69% in borderline tumor, and 78.10% in epithelial ovarian cancer, respectively. Positive expression of DNAJB11 protein was significantly higher than the rest of the ovarian tissues and normal ovarian tissues (<0.001).Higher expression of DNAJB11 was more prevalent in tissues from patients with advanced FIGO stages, high serum CA125, poor histological differentiation, and serous cancer. Kaplan-Meier curves revealed that higher expression of DNAJB11 was significantly associated with poor disease-free survival and overall survival.Multivariate survival analysis revealed that strong positive expression of DNAJB11 was an independent prognostic factor for disease-free survival and overall survival.DNAJB11 may play a role in tumorigenesis and progression of epithelial ovarian cancer.Strong positive expression of DNAJB11 was an independent prognostic factor in epithelial ovarian cancer.